-transparent.png){kind=logo}
Pharmacokinetics and clinical effects of muzolimine were investigated in 6 hypertensive patients with incipient renal insufficiency. Muzolimine plasma levels were determined after the first dose and after 8 weeks of treatment with muzolimine (20 mg o.d.). The area under the curve of muzolimine plasma levels was greater after 8 weeks than after the first dose. Also, peak plasma concentrations were higher after 8 weeks; however, muzolimine half-lives in the beta-phase were unchanged. Blood pressure and body weight decreased with time. Muzolimine was well tolerated.
Related Publications
J Mann, and
W Ritter, and
N Heckmann, and
F Sörgel, and
E Ritz
January 1989,
European journal of clinical pharmacology,
J Mann, and
W Ritter, and
N Heckmann, and
F Sörgel, and
E Ritz
January 2017,
Antimicrobial agents and chemotherapy,
J Mann, and
W Ritter, and
N Heckmann, and
F Sörgel, and
E Ritz
November 1986,
Kidney international,
J Mann, and
W Ritter, and
N Heckmann, and
F Sörgel, and
E Ritz
January 1988,
Reviews of infectious diseases,
J Mann, and
W Ritter, and
N Heckmann, and
F Sörgel, and
E Ritz
August 2002,
Cancer chemotherapy and pharmacology,
J Mann, and
W Ritter, and
N Heckmann, and
F Sörgel, and
E Ritz
October 1980,
European journal of clinical pharmacology,
J Mann, and
W Ritter, and
N Heckmann, and
F Sörgel, and
E Ritz
June 2006,
Methods and findings in experimental and clinical pharmacology,
J Mann, and
W Ritter, and
N Heckmann, and
F Sörgel, and
E Ritz
December 1978,
European journal of clinical pharmacology,
J Mann, and
W Ritter, and
N Heckmann, and
F Sörgel, and
E Ritz
January 1985,
Zeitschrift fur Kardiologie,
J Mann, and
W Ritter, and
N Heckmann, and
F Sörgel, and
E Ritz
June 1987,
Pathologie-biologie,
